Close Menu
March 18, 2020
Sponsored by

Comparison of Genome-Wide versus Targeted cfDNA Testing for First-Line Prenatal Screening: Real-World Data


Senior Medical Consultant, University Hospital Brugmann, Université Libre de Bruxelles

This webinar discusses data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Rapid global adoption of noninvasive prenatal testing (NIPT) by cell-free DNA analysis into clinical care has led to a growing number of technical approaches and menu options. With increasing frequency, the commercial availability of a test greatly precedes the presentation of peer-reviewed data evaluating performance and clinical utility, making it difficult for clinicians to differentiate how the test may impact clinical care. In order to provide high-quality patient care, laboratories and clinicians must have access to evidence that allows critical evaluation of testing options.

In this webinar, Dr. Elisa Bevilacqua of Brugmann University Hospital presents data from a recent study evaluating two cell-free DNA tests as first-line prenatal screens in Belgium: a genome-wide massively parallel sequencing test and a targeted Harmony Prenatal test performed in a local clinical laboratory.

Dr. Bevilacqua describes results comparing sensitivities, false positive rates, failure rates, and turn-around-times, and discuss the clinical utility of additional findings beyond the common trisomies revealed by genome-wide cell-free DNA analysis.

Sponsored by

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. 

Sponsored by

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.